Status:
WITHDRAWN
AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC
Lead Sponsor:
ETOP IBCSG Partners Foundation
Collaborating Sponsors:
Amgen
Eisai Inc.
Conditions:
Metastatic Non Small Cell Lung Cancer
KRAS G12C
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
AMBER is a multicentre, single-arm phase II trial. The protocol treatment consists of of sotorasib plus lenvatinib, as a second-line treatment. The primary objective of the trial is to evaluate the cl...
Eligibility Criteria
Inclusion
- Pathologically documented metastatic NSCLC.
- Documented disease progression on prior treatment. Prior treatment must have included platinum-based doublet chemotherapy and immune-checkpoint inhibition.
- KRASG12C-mutation (identified through local molecular testing, using a validated test).
- Measurable disease per RECIST v1.1 criteria.
- Age ≥18 years.
- ECOG Performance Status of 0-1.
- Life expectancy of \>3 months.
- Ability to swallow oral medications and willing to complete a treatment diary.
- Adequate haematological function.
- Adequate renal function.
- Adequate liver function.
- Men and women of childbearing potential must use highly effective contraception.
- Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test within 5 weeks before enrolment. Pregnancy test must be repeated within 3 days before the first dose of protocol treatment.
- Written IC for study participation must be signed and dated by the patient and the investigator prior to any study-related intervention.
Exclusion
- Active brain metastases E.g., untreated brain lesions (new or progressing) and/or symptomatic brain lesions (symptoms as determined by the investigator).
- Patients who have had brain metastases resected or have received whole brain radiation therapy ending at least 4 weeks (or stereotactic radiosurgery ending at least 2 weeks) prior to enrolment are eligible if they meet all of the following criteria:
- Residual neurological symptoms are only of grade ≤2
- On stable doses of dexamethasone or equivalent for at least 2 weeks, if applicable.
- History or presence of haematological malignancies. Exception: curatively treated haematological malignancies with no disease evidence in the last 2 years.
- History of (non-infectious) pneumonitis that required steroids or evidence of ILD/pneumonitis.
- Active hepatitis B and C and uncontrolled HIV.
- Uncontrolled blood pressure (systolic blood pressure \>150 mmHg or diastolic blood pressure \>90 mmHg) in spite of an optimised regimen of antihypertensive medication.
- Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, long QT syndrome (LQTS), unstable angina, myocardial infarction or stroke within 6 months before enrolment, or cardiac arrhythmia requiring medical treatment at screening
- Bleeding or thrombotic disorders or patients at risk for severe haemorrhage. The degree of tumour invasion/infiltration of major blood vessels (e.g. carotid artery) should be considered because of the potential risk of severe haemorrhage associated with tumour shrinkage/necrosis following lenvatinib therapy.
- Current or recent (within 10 days of enrolment) use of aspirin (\>325 mg/day) or treatment with dipyramidole, ticlopidine, clopidogrel, or clostazol.
- Electrolyte abnormalities that have not been corrected.
- Proteinuria on urine dipstick testing \>1+, unless a 24-hour urine collection for quantitative assessment indicates that the urine protein is \<2 g/24 hours.
- History of abdominal or tracheoesophageal fistula or gastrointestinal perforation within 6 months prior to inclusion.
- Unresolved toxicities from previous lines of anti-cancer treatment regimens and/or (with the exception of alopecia) complications from major surgery prior to enrolment.
- Previous treatment with KRAS- and/or VEGF/R inhibitors.
- Hypersensitivity to sotorasib or lenvatinib.
- Women who are pregnant or breastfeeding or who are planning to become pregnant or breastfeed.
- Sexually active men and women of childbearing potential who are not willing to use a highly effective contraceptive method during the trial and for 7 days after the last dose of sotorasib and until 30 days after the last dose of lenvatinib.
- Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
Key Trial Info
Start Date :
March 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2026
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT06068153
Start Date
March 1 2025
End Date
December 30 2026
Last Update
November 20 2024
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Innsbruck / UK für Innere Medizin V
Innsbruck, Austria
2
University Hospital of Munich (LMU), Department of Medicine V (Pneumology/Thoracic Oncology)
Munich, Germany
3
Alicante University Dr Balmis Hospital ISABIAL
Alicante, Spain
4
Ico Badalona - Hospital Germans Trias I Pujol
Badalona, Spain